Guidelines for acute management of hyperammonemia in the Middle East region

Majid Alfadhel 1, Fuad Al Mutairi 1, Nawal Makhseed 2, Fatma Al Jasmi 3, Khalid Al-Thihli 4, Emtithal Al-Jishi 5, Moeenaldeen AlSayed 6, Zuhair N Al-Hassnan 7, Fathiya Al-Murshedi 4, Johannes Häberle 8, Tawfeg Ben-Omran 9

Affiliations

doi: 10.2147/TCRM.S9314431/

Abstract

Background: Hyperammonemia is a life-threatening event that can occur at any age. If treated, the early symptoms in all age groups could be reversible. If untreated, hyperammonemia could be toxic and cause irreversible brain damage to the developing brain.

Objective: There are major challenges that worsen the outcome of hyperammonemic individuals in the Middle East. These include: lack of awareness among emergency department physicians about proper management of hyperammonemia, strained communication between physicians at primary, secondary, and tertiary hospitals, and shortage of the medications used in the acute management of hyperammonemia. Therefore, the urge to develop regional guidelines is extremely obvious.

Method: We searched PubMed and Embase databases to include published materials from 2011 to 2014 that were not covered by the European guidelines, which was published in 2012. We followed the process of a Delphi conference and involved one preliminary meeting and two follow-up meetings with email exchanges between the Middle East Hyperammonemia and Urea Cycle Disorders Scientific Group regarding each draft of the manuscript.

Results and discussion: We have developed consensus guidelines based on the highest available level of evidence. The aim of these guidelines is to homogenize and harmonize the treatment protocols used for patients with acute hyperammonemia, and to provide a resource to not only metabolic physicians, but also physicians who may come in contact with individuals with acute hyperammonemia.

Conclusion: These suggested guidelines aim to ease the challenges faced by physicians dealing with acute hyperammonemia in the region. In addition, guidelines have demonstrated useful collaboration between experts in the region, and provides information that will hopefully improve the outcomes of patients with acute hyperammonemia.

Keywords: Middle East; acute management; ammonia; hyperammonemia; inborn errors of metabolism; urea cycle.

Similar articles

Clinical and biochemical aspects of primary and secondary hyperammonemic disorders.

Häberle J.Arch Biochem Biophys. 2013 Aug 15;536(2):101-8. doi: 10.1016/j.abb.2013.04.009. Epub 2013 Apr 27.PMID: 23628343 Review.

The utility of EEG monitoring in neonates with hyperammonemia due to inborn errors of metabolism.

Wiwattanadittakul N, Prust M, Gaillard WD, Massaro A, Vezina G, Tsuchida TN, Gropman AL.Mol Genet Metab. 2018 Nov;125(3):235-240. doi: 10.1016/j.ymgme.2018.08.011. Epub 2018 Aug 24.PMID: 30197275

Inborn Errors of Metabolism with Hyperammonemia: Urea Cycle Defects and Related Disorders.

Summar ML, Mew NA.Pediatr Clin North Am. 2018 Apr;65(2):231-246. doi: 10.1016/j.pcl.2017.11.004. Epub 2018 Feb 2.PMID: 29502911 Review.

Hyperammonemia in urea cycle disorders: role of the nephrologist.

Mathias RS, Kostiner D, Packman S.Am J Kidney Dis. 2001 May;37(5):1069-80. doi: 10.1016/s0272-6386(05)80026-5.PMID: 11325692 Review.

Suggested guidelines for the diagnosis and management of urea cycle disorders: First revision.

Häberle J, Burlina A, Chakrapani A, Dixon M, Karall D, Lindner M, Mandel H, Martinelli D, Pintos-Morell G, Santer R, Skouma A, Servais A, Tal G, Rubio V, Huemer M, Dionisi-Vici C.J Inherit Metab Dis. 2019 Nov;42(6):1192-1230. doi: 10.1002/jimd.12100. Epub 2019 May 15.PMID: 30982989 Review.

Cited by

Anesthesia management in living-donor liver transplantation in a patient with carbamoyl phosphate synthetase deficiency: a case report.

Matsushita H, Fujiyoshi T, Yoshimaru K, Matsuura T, Mushimoto Y, Karashima Y, Yamaura K.JA Clin Rep. 2022 Sep 7;8(1):71. doi: 10.1186/s40981-022-00558-9.PMID: 36070152 Free PMC article.

Hepatic Encephalopathy and Melatonin.

Arjunan A, Sah DK, Jung YD, Song J.Antioxidants (Basel). 2022 Apr 25;11(5):837. doi: 10.3390/antiox11050837.PMID: 35624703 Free PMC article. Review.

Characteristics of continuous venovenous hemodiafiltration in the acute treatment of inherited metabolic disorders.

Eminoğlu FT, Öncül Ü, Kahveci F, Okulu E, Kraja E, Köse E, Kendirli T.Pediatr Nephrol. 2022 Jun;37(6):1387-1397. doi: 10.1007/s00467-021-05329-9. Epub 2021 Oct 25.PMID: 34693482 Free PMC article.

Challenges in the diagnosis and management of urea cycle disorders in Romanian children.

Pop TL, Grama A, Miclea D, Vulturar R, Benţa G, Grigore M, Simu C.Med Pharm Rep. 2021 Aug;94(Suppl No 1):S36-S39. doi: 10.15386/mpr-2226. Epub 2021 Aug 10.PMID: 34527907 Free PMC article.

[Application of continuous renal replacement therapy in the treatment of neonates with inherited metabolic diseases].

Hu Y, Peng XM, Xiao ZH.Zhongguo Dang Dai Er Ke Za Zhi. 2021 May;23(5):488-493. doi: 10.7499/j.issn.1008-8830.2101073.PMID: 34020739 Free PMC article. Chinese.

KMEL References

https://pubmed.ncbi.nlm.nih.gov/

References

  1.  
    1. Auron A, Brophy PD. Hyperammonemia in review: pathophysiology, diagnosis, and treatment. Pediatr Nephrol. 2012;27(2):207–222. - PubMed
  2.  
    1. Haberle J. Clinical practice: the management of hyperammonemia. Eur J Pediatr. 2011;170(1):21–34. - PubMed
  3.  
    1. Braissant O. Current concepts in the pathogenesis of urea cycle disorders. Mol Genet Metab. 2010;100(Suppl 1):S3–S12. - PubMed
  4.  
    1. Braissant O, McLin VA, Cudalbu C. Ammonia toxicity to the brain. J Inherit Metab Dis. 2013;36(4):595–612. - PubMed
  5.  
    1. Gropman AL, Summar M, Leonard JV. Neurological implications of urea cycle disorders. J Inherit Metab Dis. 2007;30(6):865–879. - PMC - PubMed
  6.  
    1. Kido J, Nakamura K, Mitsubuchi H, et al. Long-term outcome and intervention of urea cycle disorders in Japan. J Inherit Metab Dis. 2012;35(5):777–785. - PubMed
  7.  
    1. Msall M, Batshaw ML, Suss R, Brusilow SW, Mellits ED. Neurologic outcome in children with inborn errors of urea synthesis. Outcome of urea-cycle enzymopathies. N Engl J Med. 1984;310(23):1500–1505. - PubMed
  8.  
    1. Picca S, Dionisi-Vici C, Abeni D, et al. Extracorporeal dialysis in neonatal hyperammonemia: modalities and prognostic indicators. Pediatr Nephrol. 2001;16(11):862–867. - PubMed
  9.  
    1. Al-Shamsi A, Hertecant JL, Al-Hamad S, Souid AK, Al-Jasmi F. Mutation spectrum and birth prevalence of inborn errors of metabolism among Emiratis: a study from Tawam Hospital Metabolic Center, United Arab Emirates. Sultan Qaboos Univ Med J. 2014;14(1):e42–e49. - PMC - PubMed
  10.  
    1. Moammar H, Cheriyan G, Mathew R, Al-Sannaa N. Incidence and patterns of inborn errors of metabolism in the Eastern Province of Saudi Arabia, 1983–2008. Ann Saudi Med. 2010;30(4):271–277. - PMC - PubMed
  11.  
    1. Saadallah AA, Rashed MS. Newborn screening: experiences in the Middle East and North Africa. J Inherit Metab Dis. 2007;30(4):482–489. - PubMed
  12.  
    1. Joshi SN, Hashim J, Venugopalan P. Pattern of inborn errors of metabolism in an Omani population of the Arabian Peninsula. Ann Trop Paediatr. 2002;22(1):93–96. - PubMed
  13.  
    1. El-Mouzan MI, Al-Salloum AA, Al-Herbish AS, Qurachi MM, Al-Omar AA. Regional variations in the prevalence of consanguinity in Saudi Arabia. Saudi Med J. 2007;28(12):1881–1884. - PubMed
  14.  
    1. Tadmouri GO, Al Ali MT, Al-Haj Ali S, Al Khaja N. CTGA: the database for genetic disorders in Arab populations. Nucleic Acids Res. 2006;34(Database issue):D602–D606. - PMC - PubMed
  15.  
    1. Tadmouri GO, Nair P, Obeid T, Al Ali MT, Al Khaja N, Hamamy HA. Consanguinity and reproductive health among Arabs. Reprod Health. 2009;6:17. - PMC - PubMed
  16.  
    1. Al-Owain M, Al-Zaidan H, Al-Hassnan Z. Map of autosomal recessive genetic disorders in Saudi Arabia: concepts and future directions. Am J Med Genet A. 2012;158A(10):2629–2640. - PubMed
  17.  
    1. Haberle J, Boddaert N, Burlina A, et al. Suggested guidelines for the diagnosis and management of urea cycle disorders. Orphanet J Rare Dis. 2012;7:32. - PMC - PubMed
  18.  
    1. Baumgartner MR, Horster F, Dionisi-Vici C, et al. Proposed guidelines for the diagnosis and management of methylmalonic and propionic acidemia. Orphanet J Rare Dis. 2014;9:130. - PMC - PubMed
  19.  
    1. Rafique M. Emerging trends in management of propionic acidemia. Arq Bras Endocrinol Metabol. 2014;58(3):237–242. - PubMed
  20.  
    1. Lee HH, Poon KH, Lai CK, et al. Hyperornithinaemia-hyperammonaemia-homocitrullinuria syndrome: a treatable genetic liver disease warranting urgent diagnosis. Hong Kong Med J. 2014;20(1):63–66. - PubMed
  21.  
    1. Van Leynseele A, Jansen A, Goyens P, et al. Early treatment of a child with NAGS deficiency using N-carbamyl glutamate results in a normal neurological outcome. Eur J Pediatr. 2014;173(12):1635–1638. - PubMed
  22.  
    1. Nakamura K, Yamane K, Shinohara K, et al. Hyperammonemia in idiopathic epileptic seizure. Am J Emerg Med. 2013;31(10):1486–1489. - PubMed
  23.  
    1. Vergano SA, Crossette JM, Cusick FC, Desai BR, Deardorff MA, Sondheimer N. Improving surveillance for hyperammonemia in the newborn. Mol Genet Metab. 2013;110(1–2):102–105. - PMC - PubMed
  24.  
    1. Tummolo A, Favia V, Bellantuono R, et al. Successful early management of a female patient with a metabolic stroke due to ornithine transcarbamylase deficiency. Pediatr Emerg Care. 2013;29(5):656–658. - PubMed
  25.  
    1. Haberle J. Clinical and biochemical aspects of primary and secondary hyperammonemic disorders. Arch Biochem Biophys. 2013;536(2):101–108. - PubMed
  26.  
    1. Lamb S, Aye CY, Murphy E, Mackillop L. Multidisciplinary management of ornithine transcarbamylase (OTC) deficiency in pregnancy: essential to prevent hyperammonemic complications. BMJ Case Rep. 2013;2013:bcr2012007416. - PMC - PubMed
  27.  
    1. Chan E, McQueen F. Valproate-induced hyperammonaemia superimposed upon severe neuropsychiatric lupus: a case report and review of the literature. Clin Rheumatol. 2013;32(3):403–407. - PubMed
  28.  
    1. Tranah TH, Vijay GK, Ryan JM, Shawcross DL. Systemic inflammation and ammonia in hepatic encephalopathy. Metab Brain Dis. 2013;28(1):1–5. - PubMed
  29.  
    1. Zhang Y, Landau YE, Miller DT, Marsden D, Berry GT, Kellogg MD. Recurrent unexplained hyperammonemia in an adolescent with arginase deficiency. Clin Biochem. 2012;45(18):1583–1586. - PubMed
  30.  
    1. Mehta N, Kirk PC, Holder R, Precheur HV. Urea cycle disorder – argininosuccinic lyase deficiency. Spec Care Dentist. 2012;32(4):155–159. - PubMed
  31.  
    1. Oliva Rodriguez R, Suleiman Martos Y, Pereira Cunnil JL, Serrano Aguayo P, Garcia Alfaro C, Garcia Luna PP. Hyperammonemic encephalopathy: nutritional assessment and management of a case. Nutr Hosp. 2012;27(1):303–305. - PubMed
  32.  
    1. Nagamani SC, Erez A, Lee B. Argininosuccinate lyase deficiency. Genet Med. 2012;14(5):501–507. - PMC - PubMed
  33.  
    1. Iyer H, Sen M, Prasad C, Rupar CA, Lindsay RM. Coma, hyperammonemia, metabolic acidosis, and mutation: lessons learned in the acute management of late onset urea cycle disorders. Hemodial Int. 2012;16(1):95–100. - PubMed
  34.  
    1. Bergmann KR, McCabe J, Smith TR, Guillaume DJ, Sarafoglou K, Gupta S. Late-onset ornithine transcarbamylase deficiency: treatment and outcome of hyperammonemic crisis. Pediatrics. 2014;133(4):e1072–e1076. - PubMed
  35.  
    1. Cartagena A, Prasad AN, Rupar CA, et al. Recurrent encephalopathy: NAGS (N-acetylglutamate synthase) deficiency in adults. Can J Neurol Sci. 2013;40(1):3–9. - PMC - PubMed
  36.  
    1. Labarthe F, Tardieu M, de Parscau L, Lamireau D. Clinical presentation of inborn metabolic diseases in the neonatal period. Arch Pediatr. 2012;19(9):953–958. - PubMed
  37.  
    1. Gupta N, Kabra M. Acute management of sick infants with suspected inborn errors of metabolism. Indian J Pediatr. 2011;78(7):854–859. - PubMed
  38.  
    1. Picca S, Dionisi-Vici C, Bartuli A, et al. Short-term survival of hyperammonemic neonates treated with dialysis. Pediatr Nephrol. 2015;30(5):839–847. - PubMed
  39.  
    1. Andrews J, Guyatt G, Oxman AD, et al. GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol. 2013;66(7):719–725. - PubMed
  40.  
    1. Balshem H, Helfand M, Schunemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64(4):401–406. - PubMed
  41.  
    1. Guyatt GH, Norris SL, Schulman S, et al. Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):53S–70S. - PMC - PubMed
  42.  
    1. Terracciano L, Brozek J, Compalati E, Schunemann H. GRADE system: new paradigm. Curr Opin Allergy Clin Immunol. 2010;10(4):377–383. - PubMed
  43.  
    1. Summar M. Current strategies for the management of neonatal urea cycle disorders. J Pediatr. 2001;138(1 Suppl):S30–S39. - PubMed
  44.  
    1. Hazinski MF, Nolan JP, Billi JE, et al. Part 1: Executive summary: 2010 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science with Treatment Recommendations. Circulation. 2010;122(16 Suppl 2):S250–S275. - PubMed
  45.  
    1. Colombo JP, Peheim E, Kretschmer R, Dauwalder H, Sidiropoulos D. Plasma ammonia concentrations in newborns and children. Clin Chim Acta. 1984;138(3):283–291. - PubMed
  46.  
    1. Nagamani SCS, Erez A, Lee B. Argininosuccinate lyase deficiency. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, Bird TD, Fong CT, Mefford HC, Smith RJH, Stephens K, editors. SourceGeneReviews® [Internet] Seattle (WA): University of Washington, Seattle; 1993–2016. Feb 3, 2011. updated February 2, 2012.
  47.  
    1. Association CD. Manual of Clinical Dietetics. 5 edition. Chicago, IL: American Dietetic Association; 1996.
  48.  
    1. Chapman KA, Gropman A, MacLeod E, et al. Acute management of propionic acidemia. Mol Genet Metab. 2012;105(1):16–25. - PMC - PubMed
  49.  
    1. Brusilow SW, Maestri NE. Urea cycle disorders: diagnosis, pathophysiology, and therapy. Adv Pediatr. 1996;43:127–170. - PubMed
  50.  
    1. Leonard JV, Morris AA. Urea cycle disorders. Semin Neonatol. 2002;7(1):27–35. - PubMed
  51.  
    1. Picca S, Bartuli A, Dionisi-Vici C. Medical management and dialysis therapy for the infant with an inborn error of metabolism. Semin Nephrol. 2008;28(5):477–480. - PubMed
  52.  
    1. Hanudel M, Avasare S, Tsai E, Yadin O, Zaritsky J. A biphasic dialytic strategy for the treatment of neonatal hyperammonemia. Pediatr Nephrol. 2014;29(2):315–320. - PMC - PubMed
  53.  
    1. Batshaw ML, MacArthur RB, Tuchman M. Alternative pathway therapy for urea cycle disorders: twenty years later. J Pediatr. 2001;138(1 Suppl):S46–S54. discussion S54–S55. - PubMed
  54.  
    1. Romero-Gomez M, Jover M, Galan JJ, Ruiz A. Gut ammonia production and its modulation. Metab Brain Dis. 2009;24(1):147–157. - PubMed
  55.  
    1. Vince AJ, Burridge SM. Ammonia production by intestinal bacteria: the effects of lactose, lactulose and glucose. J Med Microbiol. 1980;13(2):177–191. - PubMed
  56.  
    1. Aires CC, van Cruchten A, Ijlst L, et al. New insights on the mechanisms of valproate-induced hyperammonemia: inhibition of hepatic N-acetylglutamate synthase activity by valproyl-CoA. J Hepatol. 2011;55(2):426–434. - PubMed
  57.  
    1. Krivitzky L, Babikian T, Lee HS, Thomas NH, Burk-Paull KL, Batshaw ML. Intellectual, adaptive, and behavioral functioning in children with urea cycle disorders. Pediatr Res. 2009;66(1):96–101. - PMC - PubMed

Page Navigation